Scotland follows NICE with no to Novartis's Afinitor and Celgene's Vidaza
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology appraisal body, said on 12 April that it would not be recommending Novartis's Afinitor (everolimus) for the treatment of advanced renal cell carcinoma (RCC) or Celgene's Vidaza (azacitidine) for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia on the Scottish NHS.